XOMA Royalty (XOMA) Competitors $27.71 +1.25 (+4.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, DVAX, INVA, NVAX, MNKD, OPK, GERN, RGLS, MYGN, and ZBIOShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA Dynavax Technologies Innoviva Novavax MannKind OPKO Health Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Do institutionals & insiders believe in XOMAO or XOMA? 95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor XOMAO or XOMA? In the previous week, XOMA Royalty's average media sentiment score of 0.74 beat XOMA's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media. Company Overall Sentiment XOMA Neutral XOMA Royalty Positive Which has higher earnings & valuation, XOMAO or XOMA? XOMA has higher earnings, but lower revenue than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$13.05MN/AN/AN/AN/AXOMA Royalty$28.49M11.64-$13.82M-$1.15-24.10 Do analysts prefer XOMAO or XOMA? XOMA Royalty has a consensus target price of $69.50, indicating a potential upside of 150.81%. Given XOMA Royalty's stronger consensus rating and higher probable upside, analysts plainly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XOMAO or XOMA more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -13.04%. XOMA's return on equity of 0.00% beat XOMA Royalty's return on equity.Company Net Margins Return on Equity Return on Assets XOMAN/A N/A N/A XOMA Royalty -13.04%-12.43%-4.85% SummaryXOMA Royalty beats XOMA on 7 of the 10 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$316.64M$2.90B$5.51B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E Ratio-24.1021.0128.0520.15Price / Sales11.64294.68438.14127.85Price / CashN/A41.8337.0657.97Price / Book3.997.868.125.62Net Income-$13.82M-$54.95M$3.16B$248.50M7 Day Performance6.13%6.24%4.40%5.54%1 Month Performance9.61%5.70%4.09%7.52%1 Year Performance12.83%8.08%34.53%22.06% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.2919 of 5 stars$27.71+4.7%$69.50+150.8%+7.3%$316.64M$28.49M-24.1010High Trading VolumeXOMAOXOMAN/A$25.18-0.6%N/A+1.2%$0.00$13.05M0.0010High Trading VolumeDVAXDynavax Technologies4.3565 of 5 stars$10.30+0.3%$24.00+133.0%-5.3%$1.23B$277.25M-19.81350INVAInnoviva4.2829 of 5 stars$18.91-1.6%$55.00+190.9%+16.0%$1.21B$358.71M-18.72100Positive NewsNVAXNovavax4.4629 of 5 stars$6.61-2.8%$17.00+157.2%-41.6%$1.10B$682.16M2.491,990MNKDMannKind2.5142 of 5 stars$3.54-1.7%$10.33+191.9%-32.8%$1.09B$285.50M35.40400OPKOPKO Health4.5292 of 5 stars$1.34-1.5%$2.75+105.2%+5.4%$1.08B$713.10M-19.142,997GERNGeron2.8304 of 5 stars$1.37-4.2%$5.06+269.5%-69.3%$910.79M$76.99M-6.5270RGLSRegulus Therapeutics1.5739 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.1336 of 5 stars$5.29-5.5%$14.38+171.9%-78.0%$516.19M$837.60M-4.722,700ZBIOZenas BioPharma1.2012 of 5 stars$9.79-2.4%$36.67+274.5%N/A$419.60M$5M0.00N/A Related Companies and Tools Related Companies XOMA Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Novavax Alternatives MannKind Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Myriad Genetics Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XOMA Stock Alerts